conducted a 1000-patient cohort study in which they identified a 153 gene signature for pathological angiogenesis that was predictive for poor prognosis and decreased patient survival in luminal A, luminal B, and basal, but surprisingly, not HER2-positive, breast cancer subtypes (46, 47). This evidence concerns the gene ERBB2 and breast carcinoma.